SYS-CON MEDIA Authors: Liz McMillan, Pat Romanski, Doug Masi, Mat Mathews, PR.com Newswire

News Feed Item

Face2Gene Mobile App Uses Facial Photos to Investigate Childhood Genetic Syndromes

FDNA launches Face2Gene[TM], a search and reference mobile app powered by its proprietary Facial Dysmorphology Novel Analysis technology

NEW YORK, March 19, 2014 /PRNewswire/ --



FDNA® (http://www.fdna.com) - a pioneer in computer-aided dysmorphology analysis has announced the availability of Face2Gene - a genetic search and reference mobile application powered by the Facial Dysmorphology Novel Analysis technology. Face2Gene facilitates detection of facial dysmorphic features and recognizable patterns of human malformations, while accessing comprehensive and up-to-date genetic references. Face2Gene aids and empowers in accelerating and increasing confidence in the research and investigation of genetic syndromes.

"FDNA's game-changing technology introduces an objective computer-aided dimension to the "art of dysmorphology", transforming the analysis into an evidence-based science." Dr. Michael R. Hayden, CM, OBC,  FRSC - Chairman of FDNA's Scientific Advisory Board & Steering Committee and Editor in Chief of Clinical Genetics.

Face2Gene is easy-to-use and seamlessly integrates into user's workflow, highlighting standardized phenotype and dysmorphic features, enabling single-point access to genetic references, and building a personalized search archive with convenient peer consultation. Face2Gene is fully HIPAA  compliant adhering to applicable privacy standards.    

Face2Gene provides a unique set of features, including comprehensive search and review of multiple online resources, full HPO annotation support, and side-by-side display of similar images, enhanced by a visual display of the syndrome "Gestalt" to augment the users' evaluation. Additional tools include personal case archive management, customized reports, and a knowledge-sharing community platform with online peer-consultations.

"FDNA's solution is a huge leap forward for dysmorphology.  It saves me significant time when I'm evaluating patients in my clinic and provides me with insightful tools that help me generate a differential diagnosis." said Dr. David A. Chitayat, MD, FABMG, FACMG, FCCMG, FRCPC - Head of the Prenatal Diagnosis and Medical Genetics Program at Mount Sinai Hospital, Toronto.

"We are proud to launch Face2Gene - our unique offering for professional caregivers in the genetics community. FDNA is dedicated to providing our users with innovative solutions that help them address the urgent and unmet needs of their patients" said Mr. Dekel Gelbman, CEO of FDNA.

About  FDNA

FDNA's mission is to save lives and improve the quality of life of patients with rare or difficult-to-diagnose genetic syndromes. FDNA has developed the proprietary Facial Dysmorphology Novel Analysis technology. This cutting-edge technology facilitates comprehensive analyses of dysmorphic features and recognizable patterns of human malformations from facial photos.

Using advanced learning algorithms, the technology improves over time, referencing comprehensive phenotype databases in real-time.

Using the power of cloud-computing and a HIPAA compliant community platform, FDNA brings this innovation to mobile devices. FDNA's solutions aid and empower in accelerating and increasing confidence in the research and investigation of genetic syndromes while leveraging the ever-increasing amounts of data in human genetics and dysmorphology.

Face2Gene is a search and reference tool provided for informational purposes and not intended to replace the clinician's judgment or experience, nor should it be used to diagnose or treat medical conditions.

Media  contact:
FDNA Inc.
Shiry Benschar, Director of Marketing Communications
Tel: +1-347-305-0085
[email protected] 

http://www.fdna.com

SOURCE FDNA Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.